Marrow Access Technologies

Name

Marrow Access Technologies

Legal name

Marrow Access Technologies

Website

https://marrowaccess.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Minnetonka

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SmartShot Medical Device Sales: Sale of proprietary medical devices (SmartShot and SmartShot Ankle) to orthopedic surgeons, hospitals, and surgical centers for use in cartilage repair procedures. Revenue is generated through direct product sales to healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Marrow Access Technologies develops and sells the SmartShot® family of single-use marrow access medical devices used by orthopedic surgeons during cartilage repair procedures. The handheld instruments create precise 1mm-diameter, 6mm-deep microchannels into subchondral bone to access stem cell-rich marrow, delivering 2X greater marrow access with 66% less bone disruption than traditional mallet microfracture. The portfolio includes the general SmartShot Marrow Access Device and the anatomically contoured SmartShot Ankle device for talar dome lesions.

Product overview

Marrow Access Technologies offers the SmartShot® family of marrow access devices for bone marrow stimulation therapy in cartilage repair procedures. The portfolio consists of two products: the original SmartShot Marrow Access Device, designed for general orthopedic use delivering double the marrow access of traditional microfracture with 66% less bone disruption, and the SmartShot Ankle, a specialized variant contoured for the unique challenges of treating talar dome cartilage lesions in the foot and ankle.

Differentiator

Problem solved

Functional benefit

Brands

• SmartShot: The SmartShot marrow access device is the company's primary product - a novel medical device for bone marrow stimulation therapy used to treat cartilage defects. It delivers double the marrow access of traditional microfracture with less disruption to native bone.
• SmartShot Ankle

Products and services

• SmartShot Marrow Access Device A handheld, single-use marrow access device for orthopedic surgeons performing bone marrow stimulation therapy in cartilage repair procedures. The SmartShot device creates clean, deep, precise microchannels (1mm diameter, 6mm depth) into subchondral bone to access stem cell-rich marrow, delivering 2X greater marrow access with 66% less bone disruption than traditional mallet microfracture and avoiding the bony compaction seen with K-wire drilling or the heat damage of powered picks.
• SmartShot Ankle A specialized contoured version of the SmartShot device designed for foot and ankle surgeons treating cartilage lesions of the ankle. It navigates the talar dome anatomy and enables creation of 6mm-deep, 1mm-diameter microchannels, allowing access to posterior osteochondral defects that are difficult to reach with legacy straight instruments.

Quantifiable outcome

• 2X greater marrow access compared to traditional microfracture
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Conmed: Conmed (including its Linvatec subsidiary) sells arthroscopic instruments and powered resection/drilling tools used in cartilage repair and microfracture procedures. A direct competitor because it offers the legacy surgical instruments SmartShot aims to replace in the cartilage repair workflow.
• Geistlich Pharma: Geistlich markets Chondro-Gide, a collagen matrix commonly combined with microfracture in autologous matrix-induced chondrogenesis (AMIC) for cartilage repair. Comparable because Chondro-Gide is typically used as a biological adjunct to microfracture, putting it in direct procedural combination with SmartShot.
• Vericel: Vericel markets MACI, an autologous cultured chondrocyte implant for cartilage defects, and sits in the same orthopedic surgeon's treatment algorithm for cartilage repair. Comparable as a pure-play cartilage repair company competing for the same procedure, though at a different point in the treatment continuum (implant vs. marrow access).
• Arthrex: Arthrex is the dominant orthopedic sports-medicine device company and the primary incumbent in microfracture and cartilage repair instruments (picks, awls, PowerPick, BioCartilage). It is the most direct competitor to SmartShot because it sells the legacy tools SmartShot is designed to displace, with deep surgeon relationships across foot/ankle, knee, and shoulder.
• Anika Therapeutics: Anika Therapeutics develops and commercializes hyaluronic-acid-based cartilage therapies (e.g., Monovisc, Orthovisc, Cingal) for joint preservation and pain management. Comparable as a cartilage/joint-preservation-focused company addressing the same patient population and orthopedic decision-maker, though via injectable therapy rather than surgical access.

Broad incumbents

• Smith & Nephew: Smith & Nephew is a global orthopedic and sports medicine incumbent with a cartilage repair portfolio spanning microfracture instruments, CARTICEL autologous chondrocyte implantation, and regenerative scaffolds. Comparable to Marrow Access because it addresses the same cartilage repair decision tree across multiple joints, though as a broad portfolio player rather than a niche access device.
• Zimmer Biomet: Zimmer Biomet is a top-3 global orthopedic device manufacturer with sports medicine, foot/ankle, and cartilage repair offerings, including DeNovo NT and microfracture instrumentation. Directly comparable given overlapping call points (orthopedic surgeons) and the board overlap with former Zimmer Biomet Spine leadership.
• Stryker: Stryker is a diversified orthopedic medical device company with sports medicine and extremities franchises that market microfracture awls, drills, and cartilage repair adjuncts. Comparable as a broad incumbent competing for the same OR budget and surgeon relationships in cartilage repair and foot/ankle procedures.

Emerging players

• Isto Biologics: Isto Biologics is a smaller orthobiologics company focused on cartilage repair and bone healing, with products that can be combined with marrow stimulation procedures. Comparable as a niche emerging player in the cartilage regeneration space targeting the same surgeon specialty as Marrow Access.
• BONESUPPORT: BONESUPPORT is an orthobiologics company selling injectable bone substitute and drug-eluting technologies used in orthopedic surgery, including procedures adjacent to marrow stimulation. Comparable as an emerging player developing biologics-compatible orthopedic products that may overlap with SmartShot's biologics-plus-access positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Customer concentration

• Xx.com/MarrowAccess
• LinkedInlinkedin.com/company/marrow-access

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marrow Access Technologies